Navigation Links
Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
Date:12/8/2008

EAST BRUNSWICK, N.J., Dec. 8 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that Paul Hamelin, Presidentof Savient Pharmaceuticals will be presenting at the upcoming 27th Annual J.P. Morgan Healthcare Conference.

The presentation is scheduled to begin on Wednesday, January 14, 2009 at 4:00 p.m. PT. The Conference will be held at the Westin St. Francis Hotel in San Francisco, CAJanuary 11-15, 2009.

Individuals can listen to a live webcast of the presentation by logging on to the Investor Relations section of Savient Pharmaceuticals' web site, http://www.savient.com. A replay of the webcast will be available on the company's web site for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. The company's product development candidate, pegloticase for treatment-failure gout, has reported positive Phase 1, 2 and 3 clinical data. Patient dosing in the Phase 3 clinical studies began in June 2006; patient enrollment was completed in March 2007; and the Phase 3 clinical studies were completed in October 2007 and the BLA was filed with the FDA in October 2008. Savient has exclusively licensed worldwide rights to the technology related to pegloticase, formerly referred to as Puricase(R), from Duke University and Mountain View Pharmaceuticals, Inc. Savient's experienced management team is committed to advancing its pipeline and expanding its product portfolio by in-licensing late-stage compounds and exploring co-promotion and co-development opportunities that fit the Company's expertise in specialty pharmaceuticals and biopharmaceuticals with an initial focus in rheumatology. Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the U.S. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc. Further information on Savient can be accessed by visiting: http://www.savient.com.

SVNT-G

    Contact:
    Mary Coleman
    Director, Investor Relations
    Savient Pharmaceuticals, Inc.
    information@savient.com
    (732) 418-9300


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Savient Pharmaceuticals to Present at the Credit Suisse Phoenix Healthcare Conference on November 13th
2. Savients Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
10. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
11. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... ... They are musicians and librarians, fashion designers and fitness instructors, actors, athletes ... and around the nation. What do they have in common? All have been affected ... compelling new photographic exhibit debuting Friday, December 9 at Logan International Airport in Boston. ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... services from offices located in South Lyon, Dewitt, Williamston, East Lansing, Ann Arbor, ... coach who needs treatment for a brain tumor. , Jason Bauer and his ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... One of ... changing of the securement tape is painful for her. "This is why the co-inventor ... patients’ heads," she said. , They then created a prototype of the patent-pending AV-AIR, ...
(Date:12/7/2016)... AUSTIN, TX (PRWEB) , ... OCTOBER XX, 2016 ... ... may help solve another mystery. A new study entitled “Canine Filamentous Dermatitis ... Morgellons disease can occur in dogs. The study was published in the prestigious ...
(Date:12/7/2016)... IL (PRWEB) , ... December 07, 2016 , ... Facial ... back this holiday season by donating a portion of proceeds to two local organizations: ... North Chicago Animal Control & Friends is a team of authorized and trained ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... Today, Stock-Callers.com presents four Biotech equities ... ), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH ), ProNAi ... (NASDAQ: AVXS ). From its peak in July ... reach a level equal to what it saw at the ... for the year, it has still out-performed other market sectors, ...
(Date:12/7/2016)... Dec. 7, 2016  Lannett Company, Inc. (NYSE: LCI ... Capital Markets 2016 Prescription for Success Healthcare Conference on December 14, ... New York City . In addition, ... the Guggenheim Securities 4 th Annual Boston Healthcare Conference taking ... ...
(Date:12/6/2016)... , Dec. 6, 2016  Licenders is bringing their 100% ... new location in Park Slope at 203 13 th Street ... Brooklyn clientele. "Our goal is to ease ... plans are designed to get children right back to class without ... 100% all natural and safe for the whole family," Licenders President ...
Breaking Medicine Technology: